BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Thermo Fisher Secures FDA Approval for Oncomine Dx Express Test as Companion Diagnostic for Dizal’s ZEGFROVY

Thermo Fisher Scientific, the world leader in serving science, announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine&t...

July 04, 2025 | News

Lunit Partners with Microsoft to Scale AI-Powered Cancer Diagnostics Globally

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, announced a collaboration with Microsoft to accelerate the deliver...

July 03, 2025 | News

Dizal Secures FDA Approval for ZEGFROVY, the First Targeted Oral Therapy for EGFR Exon20ins NSCLC

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins Approval follows the U....

July 03, 2025 | News

Taiwan Steps Into the Global Spotlight With a New Cancer Therapy

Traditional therapies often fall short in targeting these aggressive cancers with precision or safety. Can SOB100 improve drug delivery without the usual s...

July 02, 2025 | Report

Duke Street Bio Secures FDA Fast Track Designation for DSB2455 in TNBC-Related Brain Metastases

Duke Street Bio, a clinical-stage biotechnology company focused on precision oncology, announced that the U.S. Food and Drug Administration (FDA) has...

June 25, 2025 | News

EVA Pharma and CHICO Pharmaceutical Join Forces to Localize Oncology API Production for Middle East and Africa

On the sidelines of CPHI China 2025, EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle Eas...

June 25, 2025 | News

Daiichi Sankyo and AstraZeneca’s DATROWAY Receives U.S. FDA Accelerated Approval for EGFR-Mutated Lung Cancer

Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and ...

June 24, 2025 | News

Harbour BioMed and Otsuka Ink $670M+ Global Deal to Advance Bispecific T-Cell Engager for Autoimmune Diseases

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology,&nb...

June 23, 2025 | News

XtalPi and DoveTree Sign $100M+ LOI to Accelerate AI-Driven Drug Discovery Across Oncology and Neurology

XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, announced it has signed a Letter of Intent (LOI) with DoveTre...

June 23, 2025 | News

Dizal Completes Enrollment for Global Phase III Trial of Sunvozertinib in EGFR exon20ins NSCLC Patients

Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the effi...

June 20, 2025 | News

Pierre Fabre Acquires Global Rights to Next-Generation EGFR Inhibitors for Lung Cancer

Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., o...

June 17, 2025 | News

Teva and Fosun Pharma Enter Strategic Partnership to Advance Anti-PD1-IL2 ATTENUKINE™ Therapy TEV-56278 for Oncology

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun...

June 17, 2025 | News

Gene Solutions and USKBio Partner to Launch AI-Powered NGS Oncology Lab in Southern China

- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator i...

June 16, 2025 | News

Sanyou Biopharmaceuticals and Medicovestor Forge Strategic Partnership to Advance First-in-Class Chemoimmunotherapy ADCs

Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D announced the signing ...

June 11, 2025 | News

Stay Connected